US 6,982,248 B2
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
Thomas R. Coolidge, Falls Village, Conn. (US); and Mario R. W. Ehlers, Lincoln, Nebr. (US)
Assigned to Amylin Pharmaceuticals, Inc., San Diego, Calif. (US)
Filed on May 09, 2001, as Appl. No. 9/851,738.
Application 09/851738 is a division of application No. 09/302596, filed on Apr. 30, 1999, granted, now 6,284,725.
Claims priority of provisional application 60/103498, filed on Oct. 08, 1998.
Prior Publication US 2002/0055460 A1, May 09, 2002
Int. Cl. A61K 38/26 (2006.01); A61K 38/28 (2006.01)
U.S. Cl. 514—3 28 Claims
 
1. A method for preventing or ameliorating a decrease in a function of a tissue, wherein the tissue has undergone an ischemia-reperfusion event sufficient to cause cell death, or reversible or irreversible cell damage in said tissue, comprising administering to an individual an effective amount of a composition comprising a compound that activates a receptor for glucagon-like peptide-1 (GLP-1) in a pharmaceutical carrier.